A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

Clinical trial NCT02237157 · COMPLETED

Trial details

NCT number: NCT02237157
Sponsor: RenovoRx
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Cancer

Start date: 2015-03-01
Primary completion: 2016-09-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.